share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer WAGNER CHARLES F JR

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer WAGNER CHARLES F JR

福泰制药 | 4:持股变动声明-高管 WAGNER CHARLES F JR
美股SEC公告 ·  05/30 16:11
Moomoo AI 已提取核心信息
Charles F. Wagner Jr., EVP & Chief Financial Officer of Vertex Pharmaceuticals Inc. (VRTX), completed a sale of 3,250 shares of common stock on May 28, 2024. The transaction was executed at a price of $454.79 per share, resulting in a total sale value of approximately $1.48 million. Following the sale, Wagner's direct holdings in the company amount to 50,387 shares. The sale took place through an open market transaction, indicating a standard practice of stock disposal by company insiders.
Charles F. Wagner Jr., EVP & Chief Financial Officer of Vertex Pharmaceuticals Inc. (VRTX), completed a sale of 3,250 shares of common stock on May 28, 2024. The transaction was executed at a price of $454.79 per share, resulting in a total sale value of approximately $1.48 million. Following the sale, Wagner's direct holdings in the company amount to 50,387 shares. The sale took place through an open market transaction, indicating a standard practice of stock disposal by company insiders.
Vertex Pharmicals Inc.(VRTX)执行副总裁兼首席财务官小查尔斯·瓦格纳于2024年5月28日完成了3,250股普通股的出售。该交易以每股454.79美元的价格执行,总销售价值约为148万美元。出售后,瓦格纳在公司的直接持股量为50,387股。此次出售是通过公开市场交易进行的,这表明了公司内部人士处置股票的标准做法。
Vertex Pharmicals Inc.(VRTX)执行副总裁兼首席财务官小查尔斯·瓦格纳于2024年5月28日完成了3,250股普通股的出售。该交易以每股454.79美元的价格执行,总销售价值约为148万美元。出售后,瓦格纳在公司的直接持股量为50,387股。此次出售是通过公开市场交易进行的,这表明了公司内部人士处置股票的标准做法。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息